Skip to main content
Shanghai Junshi Biosciences Co.,Ltd. logo

Shanghai Junshi Biosciences Co.,Ltd. — Investor Relations & Filings

Ticker · 688180 ISIN · CNE1000041Z1 LEI · 300300L36FLCKN0WXW06 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,065 across all filing types
Latest filing 2026-03-02 Report Publication Anno…
Country CN China
Listing Shanghai Stock Exchange 688180

About Shanghai Junshi Biosciences Co.,Ltd.

https://www.junshipharma.com/

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies. The company maintains a diverse pipeline targeting oncology, immunology, metabolic disorders, neurological diseases, and infectious diseases. A pioneer in its field, it developed Toripalimab, the first domestically produced anti-PD-1 monoclonal antibody to receive marketing approval in its home market. Its integrated R&D platform encompasses the entire drug development lifecycle, from initial discovery and clinical evaluation to large-scale manufacturing and global commercialization. The company collaborates with international partners to expand the reach of its innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, aiming to provide effective and affordable treatment options for patients globally.

Recent filings

Filing Released Lang Actions
君实生物H股公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement from Shanghai Junshi Biosciences Co., Ltd. regarding the scheduled date of a board meeting to consider and approve the annual results for the fiscal year ending December 31, 2025, and to consider the payment of a final dividend. The document is only 619 characters long and does not contain any actual financial data or detailed report content. It is an announcement about the timing of the board meeting where the annual results will be reviewed, not the annual report itself. According to the 'MENU VS MEAL' rule, such short announcements about report timing or meetings are classified as Report Publication Announcements (RPA).
2026-03-02 Chinese
君实生物2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025年度业绩快报公告" which translates to "2025 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2025, including revenue, profit, and other financial metrics, but explicitly states that the data is preliminary and unaudited, and the final audited data will be in the 2025 Annual Report. The document is relatively short (2387 characters) and serves as a quick earnings update rather than a full comprehensive report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of report publication but a brief financial performance summary. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2025
2026-02-27 Chinese
君实生物H股公告
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report for a listed company, Shanghai Junshi Biosciences, submitted to the Hong Kong Stock Exchange. It details changes in registered capital, issued shares, treasury shares, share options, and confirms compliance with public float requirements under the Listing Rules. The document is titled as a monthly report on securities changes and includes no financial statements or earnings data. It is a regulatory compliance filing related to share capital and shareholding changes, not a financial report or announcement of a meeting or vote. Therefore, it fits best under Regulatory Filings (RNS). The document length is over 5,000 characters and contains substantive data on share movements, but it is not a financial report or announcement of a report publication.
2026-02-25 Chinese
君实生物关于控股股东、实际控制人之一兼董事长增持股份进展公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the progress of a shareholding increase by a controlling shareholder and chairman of the company. It details the number of shares held before and after the increase, the amount of money involved, the schedule of the increase plan, and risk factors related to the shareholding increase. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory disclosure about insider share transactions by a director and controlling shareholder. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 2757 characters, which is consistent with a detailed announcement but not a full financial report. Hence, the classification is DIRS with high confidence.
2026-02-10 Chinese
君实生物H股公告
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report for Shanghai Junshi Biosciences Co., Ltd., submitted to the Hong Kong Stock Exchange. It details changes in registered capital, issued shares, share options, and confirms compliance with public float requirements under the Listing Rules. The document is titled as a monthly report and contains detailed share capital and shareholding changes, but it is not a full financial report, earnings release, or management discussion. It is a regulatory compliance report related to share capital and securities movements. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-02-04 Chinese
君实生物2025年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2025 annual performance forecast (业绩预告) issued by the company's board, providing preliminary estimated financial results for the full year 2025, including revenue, R&D expenses, and net profit projections. It explicitly states that the forecast is unaudited and that the final audited financial data will be disclosed in the formal 2025 annual report. The document length is about 2024 characters, which is relatively short and primarily serves as a performance outlook rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights and projections for the fiscal year but does not contain full audited financial statements or detailed analysis. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and is a forecast rather than a report. It is not a Report Publication Announcement (RPA) because it contains substantive financial forecast data rather than just announcing a report's release. Therefore, the best classification is Earnings Release (ER). FY 2025
2026-01-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.